Other Stories

Full Video

Celltrion developing cocktail antibody that could treat Omicron variant Updated: 2021-11-29 17:18:07 KST

South Korean biopharmaceutical company Celltrion is working towards developing an inhalable COVID-19 treatment that can treat variants including the Omicron strain.
On Monday, Celltrion said it found its antibody candidate "CT-P63" to have qualities that could fight against the Omicron variant.
The company has recently finished administering the drug to participants in its phase 1 clinical trial.
Though further research is needed, Celltrion said once it certifies the efficacy of this candidate antibody, it will combine it with its already developed treatment "Regkirona" and create an inhalable treatment.
KOGL : Korea Open Government License
본 저작물 중 본문에 해당하는 뉴스 스크립트(텍스트)는 공공누리 제1유형-출처표시 조건에 따라 이용할 수 있습니다.